EAPIF: AI 评分 38/100 — AI 分析 (4月 2026)

Euroapi S.A. is a European company focused on the development, manufacturing, and distribution of active pharmaceutical ingredients (APIs) and intermediates. These products are essential for formulating medicines for both human and veterinary use.

Key Facts: AI Score: 38/100 Sector: Healthcare

公司概况

概要：

Euroapi S.A., incorporated in 2021 and based in Paris, develops, manufactures, and distributes active pharmaceutical ingredients (APIs) and intermediates crucial for human and veterinary medicines. With a focus on the healthcare sector, Euroapi faces competitive pressures and financial challenges reflected in its negative P/E ratio.

EAPIF是做什么的？

Euroapi SA, established in 2021 and headquartered in Paris, France, specializes in the development, manufacture, and distribution of active pharmaceutical ingredients (APIs) and intermediates. These essential components are used in formulating a wide range of medicines for both human and veterinary applications. As a relatively new entity, Euroapi has quickly positioned itself within the competitive pharmaceutical supply chain, focusing on providing high-quality ingredients to pharmaceutical companies globally. The company's product portfolio includes a diverse array of APIs and intermediates, catering to various therapeutic areas. Euroapi's business model centers around supplying these ingredients to pharmaceutical manufacturers, who then use them to produce finished drug products. Euroapi's geographic reach extends across Europe and beyond, with a focus on serving the needs of pharmaceutical companies in key markets. Euroapi faces competition from other API manufacturers, both large and small, operating on a global scale. The company differentiates itself through its commitment to quality, reliability, and customer service. Despite being a relatively young company, Euroapi has established a presence in the API market and continues to expand its product offerings and customer base. The company's focus on APIs and intermediates positions it as a critical player in the pharmaceutical supply chain, supporting the development and manufacturing of essential medicines.

EAPIF的投资论点是什么？

Euroapi S.A. presents a complex investment case. The company operates in the essential active pharmaceutical ingredients (API) market. A key value driver is its role in the pharmaceutical supply chain, providing ingredients for both human and veterinary medicines. However, the company's negative P/E ratio of -0.57 and a negative profit margin of -24.8% indicate financial challenges. Growth catalysts include potential expansion of its product portfolio and increased demand for APIs. The company's beta of 0.60 suggests lower volatility compared to the market. Potential risks include competitive pressures from established API manufacturers and the financial performance. Investors should carefully consider these factors when evaluating Euroapi's investment potential.

EAPIF在哪个行业运营？

Euroapi S.A. operates within the active pharmaceutical ingredients (API) market, a critical segment of the broader pharmaceutical industry. The API market is characterized by increasing demand, driven by the growing global population and the rising prevalence of chronic diseases. Competition is intense, with numerous players vying for market share. Euroapi's focus on APIs for both human and veterinary medicines positions it in a growing market, but its financial performance needs improvement to compete effectively.

Medical - Devices

Healthcare

EAPIF有哪些增长机遇？

Expansion of API Portfolio: Euroapi can expand its portfolio of active pharmaceutical ingredients to cater to a broader range of therapeutic areas. This includes investing in research and development to create new APIs and intermediates, as well as acquiring existing product lines. The global API market is projected to reach $274.9 billion by 2033, presenting a significant opportunity for Euroapi to increase its market share. Timeline: Ongoing.
Geographic Expansion: Euroapi can expand its geographic reach beyond Europe to tap into new markets in Asia, North America, and Latin America. This includes establishing sales offices, distribution networks, and manufacturing facilities in key regions. The increasing demand for pharmaceuticals in emerging markets presents a significant growth opportunity for Euroapi. Timeline: Ongoing.
Strategic Partnerships: Euroapi can form strategic partnerships with pharmaceutical companies, research institutions, and other organizations to accelerate its growth and expand its capabilities. This includes collaborating on research and development projects, licensing technologies, and co-marketing products. Strategic partnerships can provide Euroapi with access to new markets, technologies, and expertise. Timeline: Ongoing.
Focus on Specialty APIs: Euroapi can focus on developing and manufacturing specialty APIs, such as high-potency APIs (HPAPIs) and controlled substances. These APIs require specialized manufacturing capabilities and offer higher profit margins. The growing demand for specialty APIs presents a significant opportunity for Euroapi to differentiate itself from competitors. Timeline: Ongoing.
Vertical Integration: Euroapi can pursue vertical integration by acquiring or establishing its own manufacturing facilities for key raw materials and intermediates. This would reduce its reliance on external suppliers and improve its control over its supply chain. Vertical integration can also lead to cost savings and improved product quality. Timeline: Ongoing.

Market Cap of $0.12B indicates a relatively small company size within the pharmaceutical industry.
P/E Ratio of -0.57 reflects negative earnings, suggesting the company is currently not profitable.
Profit Margin of -24.8% highlights significant challenges in achieving profitability.
Gross Margin of 16.8% indicates the percentage of revenue exceeding the cost of goods sold.
Beta of 0.60 suggests the stock is less volatile than the overall market.

EAPIF提供哪些产品和服务？

Develops active pharmaceutical ingredients (APIs) for human medicines.
Develops active pharmaceutical ingredients (APIs) for veterinary medicines.
Manufactures APIs and intermediates used in drug formulations.
Markets APIs to pharmaceutical companies globally.
Distributes APIs through its network to reach customers.
Provides custom synthesis and manufacturing services for specific API needs.
Offers regulatory support and documentation for its APIs.

EAPIF如何赚钱？

Develops and manufactures APIs and intermediates.
Sells APIs to pharmaceutical companies for drug formulation.
Generates revenue through API sales volume and pricing.
Focuses on both human and veterinary medicine APIs.

Pharmaceutical companies formulating human drugs.
Pharmaceutical companies formulating veterinary drugs.
Generic drug manufacturers.
Research institutions and universities.

Specialized manufacturing capabilities for APIs.
Established relationships with pharmaceutical companies.
Regulatory expertise in API development and manufacturing.
Focus on both human and veterinary medicine APIs.

什么因素可能推动EAPIF股价上涨？

Upcoming: Potential expansion of API product portfolio to address new therapeutic areas.
Upcoming: Possible strategic partnerships with pharmaceutical companies to co-develop or market APIs.
Ongoing: Increasing demand for APIs due to the growing global population and prevalence of chronic diseases.
Ongoing: Efforts to improve operational efficiency and reduce production costs.
Ongoing: Regulatory approvals for new APIs in key markets.

EAPIF的主要风险是什么？

Potential: Intense competition from established API manufacturers with greater resources.
Potential: Fluctuations in raw material prices impacting production costs and profitability.
Potential: Changes in pharmaceutical regulations affecting API development and manufacturing.
Ongoing: Negative profit margin and financial instability.
Ongoing: Limited liquidity due to OTC market trading.

EAPIF的核心优势是什么？

Specialized in API development and manufacturing.
Serves both human and veterinary medicine markets.
Established presence in the European market.
Focus on quality and regulatory compliance.

EAPIF的劣势是什么？

Relatively new company (incorporated in 2021).
Negative profit margin (-24.8%).
Limited financial resources compared to larger competitors.
Dependence on pharmaceutical company demand.

EAPIF有哪些机遇？

Expanding API portfolio to new therapeutic areas.
Geographic expansion into emerging markets.
Strategic partnerships with pharmaceutical companies.
Growing demand for APIs in the pharmaceutical industry.

EAPIF面临哪些威胁？

Intense competition from established API manufacturers.
Fluctuations in raw material prices.
Changes in pharmaceutical regulations.
Economic downturns affecting pharmaceutical spending.

EAPIF的竞争对手是谁？

Clariant AG — Specialty chemicals competitor. — (CLVLF)
Cambrex Corporation — API and drug product manufacturer. — (CMVLF)
CytoDyn Inc. — Biopharmaceutical company. — (CYDY)
Demetrix, Inc. — Biotech company focused on cannabinoids. — (DMTRF)
iOnctura SA — Biopharmaceutical company developing cancer therapies. — (IOBCF)

Key Metrics

MoonshotScore: 38/100

Company Profile

CEO: David Seignolle
Headquarters: Paris, FR
Employees: 3,187
Founded: 2022

AI Insight

AI analysis pending for EAPIF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Euroapi S.A. do?

Euroapi S.A. develops, manufactures, and distributes active pharmaceutical ingredients (APIs) and intermediates, which are essential components used in the formulation of medicines for both human and veterinary use. The company operates as a supplier to pharmaceutical companies, providing them with the necessary ingredients to produce finished drug products. Euroapi's market position is focused on providing high-quality APIs and intermediates to meet the demands of the pharmaceutical industry.

What do analysts say about EAPIF stock?

Analyst consensus on EAPIF stock is currently unavailable due to limited coverage. Key valuation metrics such as price targets and ratings are not widely available. Growth considerations revolve around the company's ability to expand its API portfolio, enter new markets, and improve its financial performance. Investors should conduct their own due diligence and consider the risks and opportunities associated with investing in EAPIF.

What are the main risks for EAPIF?

The main risks for EAPIF include intense competition from established API manufacturers, fluctuations in raw material prices, changes in pharmaceutical regulations, and the company's current negative profit margin. Additionally, as an OTC-traded stock, EAPIF faces risks related to limited liquidity, potential for price volatility, and reduced regulatory oversight. Investors should carefully consider these risks before investing in EAPIF.